A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
Recruiting · NCT07604909 · Registry updated 2026-05-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Relapse, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-05-22 | NCT07604909 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fudan University | 653 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | China | 128 |